Katelyn M Rossow1,2, Ida T Aka3,2, Angela C Maxwell-Horn3, Dan M Roden4,5,6, Sara L Van Driest3,4. 1. Departments of Pediatrics, katelyn.rossow@vumc.org. 2. Contributed equally as co-first authors. 3. Departments of Pediatrics. 4. Medicine. 5. Pharmacology, and. 6. Biomedical Informatics, School of Medicine, Vanderbilt University, Nashville, Tennessee.
Abstract
OBJECTIVES: To determine the association between cytochrome P450 2C19 (CYP2C19) metabolizer status and risk for escitalopram and citalopram, collectively termed (es)citalopram, and sertraline adverse events (AEs) in children. METHODS: In this retrospective cohort study, we used deidentified electronic health records linked to DNA. The cohort included children ≤18 years with ≥2 days of (es)citalopram or ≥7 days of sertraline exposure. The primary outcome was AEs assessed by manual chart review. CYP2C19 was genotyped for functional variants (*2, *3, *4, *6, *8, and *17), and individuals were assigned metabolizer status. Association between AEs and metabolizer status was determined by using Cox regression adjusting for age, race, ethnicity, dose, and concomitant CYP2C19-inhibiting medications. RESULTS: The cohort included 249 sertraline-exposed and 458 (es)citalopram-exposed children, with a median age of 14.2 years (interquartile range 11.2-16.2) and 13.4 years (interquartile range 10.1-15.9), respectively. Sertraline AEs were more common in normal metabolizers (NMs) compared to poor metabolizers (PMs) or intermediate metabolizers (IMs) (hazard ratio [HR] 1.8; 95% confidence interval [CI] 1.01-3.2; P = .047) in unadjusted analysis and after adjustment (HR 1.9; CI 1.04-3.4; P = .04). For (es)citalopram, more AEs were observed in NMs than PMs and IMs without statistically significant differences (unadjusted HR 1.6; CI 0.95-2.6; P = .08; adjusted HR 1.6; CI 0.95-2.6; P = .08). CONCLUSIONS: In contrast to adults, in our pediatric cohort, CYP2C19 NMs experienced increased sertraline AEs than PMs and IMs. (Es)citalopram AEs were not associated with CYP2C19 status in the primary analysis. The mechanism underlying this pediatric-specific finding is unknown but may be related to physiologic differences of adolescence. Further research is required to inform genotype-guided prescribing for these drugs in children.
OBJECTIVES: To determine the association between cytochrome P450 2C19 (CYP2C19) metabolizer status and risk for escitalopram and citalopram, collectively termed (es)citalopram, and sertraline adverse events (AEs) in children. METHODS: In this retrospective cohort study, we used deidentified electronic health records linked to DNA. The cohort included children ≤18 years with ≥2 days of (es)citalopram or ≥7 days of sertraline exposure. The primary outcome was AEs assessed by manual chart review. CYP2C19 was genotyped for functional variants (*2, *3, *4, *6, *8, and *17), and individuals were assigned metabolizer status. Association between AEs and metabolizer status was determined by using Cox regression adjusting for age, race, ethnicity, dose, and concomitant CYP2C19-inhibiting medications. RESULTS: The cohort included 249 sertraline-exposed and 458 (es)citalopram-exposed children, with a median age of 14.2 years (interquartile range 11.2-16.2) and 13.4 years (interquartile range 10.1-15.9), respectively. Sertraline AEs were more common in normal metabolizers (NMs) compared to poor metabolizers (PMs) or intermediate metabolizers (IMs) (hazard ratio [HR] 1.8; 95% confidence interval [CI] 1.01-3.2; P = .047) in unadjusted analysis and after adjustment (HR 1.9; CI 1.04-3.4; P = .04). For (es)citalopram, more AEs were observed in NMs than PMs and IMs without statistically significant differences (unadjusted HR 1.6; CI 0.95-2.6; P = .08; adjusted HR 1.6; CI 0.95-2.6; P = .08). CONCLUSIONS: In contrast to adults, in our pediatric cohort, CYP2C19 NMs experienced increased sertraline AEs than PMs and IMs. (Es)citalopram AEs were not associated with CYP2C19 status in the primary analysis. The mechanism underlying this pediatric-specific finding is unknown but may be related to physiologic differences of adolescence. Further research is required to inform genotype-guided prescribing for these drugs in children.
Authors: Moira A Rynn; John T Walkup; Scott N Compton; Dara J Sakolsky; Joel T Sherrill; Sa Shen; Philip C Kendall; James McCracken; Anne Marie Albano; John Piacentini; Mark A Riddle; Courtney Keeton; Bruce Waslick; Allan Chrisman; Satish Iyengar; John S March; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-12-31 Impact factor: 8.829
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: B Carlsson; G Olsson; M Reis; J Walinder; C Nordin; J Lundmark; M G Scordo; M L Dahl; F Bengtsson; J Ahlner Journal: Ther Drug Monit Date: 2001-12 Impact factor: 3.681
Authors: D M Roden; J M Pulley; M A Basford; G R Bernard; E W Clayton; J R Balser; D R Masys Journal: Clin Pharmacol Ther Date: 2008-05-21 Impact factor: 6.875
Authors: J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk Journal: Clin Pharmacol Ther Date: 2015-06-29 Impact factor: 6.875
Authors: J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar Journal: Clin Pharmacol Ther Date: 2011-03-16 Impact factor: 6.875
Authors: Andrea Cipriani; Xinyu Zhou; Cinzia Del Giovane; Sarah E Hetrick; Bin Qin; Craig Whittington; David Coghill; Yuqing Zhang; Philip Hazell; Stefan Leucht; Pim Cuijpers; Juncai Pu; David Cohen; Arun V Ravindran; Yiyun Liu; Kurt D Michael; Lining Yang; Lanxiang Liu; Peng Xie Journal: Lancet Date: 2016-06-08 Impact factor: 79.321
Authors: Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey Journal: Front Pharmacol Date: 2019-02-19 Impact factor: 5.810
Authors: Jeffrey R Strawn; Ethan A Poweleit; Chakradhara Rao S Uppugunduri; Laura B Ramsey Journal: Front Pharmacol Date: 2021-10-01 Impact factor: 5.810